Literature DB >> 18591268

Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.

Rahul Kumar Verma1, Jatinder Kaur, Kaushlendra Kumar, Awadh Bihari Yadav, Amit Misra.   

Abstract

Intracellular concentrations of isoniazid and rifabutin resulting from administration of inhalable microparticles of these drugs to phorbol-differentiated THP-1 cells and the pharmacokinetics and biodistribution of these drugs upon inhalation of microparticles or intravenous administration of free drugs to mice were investigated. In cultured cells, both microparticles and dissolved drugs established peak concentrations of isoniazid ( approximately 1.4 and 1.1 microg/10(6) cells) and rifabutin ( approximately 2 microg/ml and approximately 1.4 microg/10(6) cells) within 10 min. Microparticles maintained the intracellular concentration of isoniazid for 24 h and rifabutin for 96 h, whereas dissolved drugs did not. The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 microg of either drug, to parallel groups): isoniazid, serum half-life (t(1/2)) = 18.63 +/- 5.89 h (3.91 +/- 1.06 h), maximum concentration in serum (C(max)) = 2.37 +/- 0.23 microg x ml(-1) (3.24 +/- 0.57 microg x ml(-1)), area under the concentration-time curve from 0 to 24 h (AUC(0-24)) = 55.34 +/- 13.72 microg/ml(-1) h(-1) (16.64 +/- 1.80 microg/ml(-1) h(-1)), and clearance (CL) = 63.90 +/- 13.32 ml x h(-1) (4.43 +/- 1.85 ml x h(-1)); rifabutin, t(1/2) = 119.49 +/- 29.62 h (20.18 +/- 4.02 h), C(max) = 1.59 +/- 0.01 microg x ml(-1) (3.47 +/- 0.33 microg x ml(-1)), AUC(0-96) = 109.35 +/- 14.78 microg/ml(-1) h(-1) (90.82 +/- 7.46 microg/ml(-1) h(-1)), and CL = 11.68 +/- 7.00 ml x h(-1) (1.03 +/- 0.11 ml.h(-1)). Drug targeting to the lungs in general and alveolar macrophages in particular was observed. It was concluded that inhaled microparticles can reduce dose frequency and improve the pharmacologic index of the drug combination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591268      PMCID: PMC2533446          DOI: 10.1128/AAC.00153-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids.

Authors:  A Hutchings; R D Monie; B Spragg; P A Routledge
Journal:  J Chromatogr       Date:  1983-10-14

Review 2.  The clinical pharmacokinetics of rifabutin.

Authors:  T F Blaschke; M H Skinner
Journal:  Clin Infect Dis       Date:  1996-04       Impact factor: 9.079

3.  Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

Authors:  H S Schaaf; D P Parkin; H I Seifart; C J Werely; P B Hesseling; P D van Helden; J S Maritz; P R Donald
Journal:  Arch Dis Child       Date:  2005-06       Impact factor: 3.791

4.  Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Authors:  Marc Weiner; Debra Benator; William Burman; Charles A Peloquin; Awal Khan; Andrew Vernon; Brenda Jones; Claudia Silva-Trigo; Zhen Zhao; Thomas Hodge
Journal:  Clin Infect Dis       Date:  2005-04-14       Impact factor: 9.079

5.  Sensitive liquid chromatographic technique to measure isoniazid in alveolar cells, bronchoalveolar lavage and plasma in HIV-infected patients.

Authors:  T Delahunty; B Lee; J E Conte
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-02-13

6.  Pharmacokinetics of rifabutin.

Authors:  M H Skinner; M Hsieh; J Torseth; D Pauloin; G Bhatia; S Harkonen; T C Merigan; T F Blaschke
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of isoniazid.

Authors:  W W Weber; D W Hein
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

9.  In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.

Authors:  T Hirata; H Saito; H Tomioka; K Sato; J Jidoi; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

Review 10.  Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; A Fitton
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

View more
  15 in total

1.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

Review 2.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

3.  Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.

Authors:  Li Liu; Youwen Xu; Colleen Shea; Joanna S Fowler; Jacob M Hooker; Peter J Tonge
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

4.  An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages.

Authors:  Tatiany J de Faria; Mariane Roman; Nicole M de Souza; Rodrigo De Vecchi; João Vitor de Assis; Ana Lúcia Gomes dos Santos; Ivan H Bechtold; Nathalie Winter; Maurilio José Soares; Luciano Paulino Silva; Mauro V De Almeida; André Báfica
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

5.  Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics.

Authors:  Yongjian Liu; Aida Ibricevic; Joel A Cohen; Jessica L Cohen; Sean P Gunsten; Jean M J Fréchet; Michael J Walter; Michael J Welch; Steven L Brody
Journal:  Mol Pharm       Date:  2009 Nov-Dec       Impact factor: 4.939

6.  Functionalization of PLGA Nanoparticles with 1,3-β-glucan Enhances the Intracellular Pharmacokinetics of Rifampicin in Macrophages.

Authors:  Matshawandile Tukulula; Luis Gouveia; Paulo Paixao; Rose Hayeshi; Brendon Naicker; Admire Dube
Journal:  Pharm Res       Date:  2018-03-29       Impact factor: 4.200

Review 7.  Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis.

Authors:  Anuradha Gupta; Amit Misra; Vojo Deretic
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

8.  Buparvaquone loaded solid lipid nanoparticles for targeted delivery in theleriosis.

Authors:  Maheshkumar P Soni; Nilakash Shelkar; Rajiv V Gaikwad; Geeta R Vanage; Abdul Samad; Padma V Devarajan
Journal:  J Pharm Bioallied Sci       Date:  2014-01

9.  Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery.

Authors:  J Varshosaz; S Ghaffari; S F Mirshojaei; A Jafarian; F Atyabi; F Kobarfard; S Azarmi
Journal:  Biomed Res Int       Date:  2013-08-01       Impact factor: 3.411

10.  Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis.

Authors:  N A Cilfone; E Pienaar; G M Thurber; D E Kirschner; J J Linderman
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.